Trade Lantern Pharma Inc. - LTRN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 3.68 |
| Open* | 3.68 |
| 1-Year Change* | -25.35% |
| Day's Range* | 3.63 - 3.73 |
| 52 wk Range | 4.05-6.20 |
| Average Volume (10 days) | 26.41K |
| Average Volume (3 months) | 883.02K |
| Market Cap | 47.93M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 10.87M |
| Revenue | N/A |
| EPS | -1.31 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 22, 2023 | 3.63 | -0.05 | -1.36% | 3.68 | 3.73 | 3.63 |
| Sep 21, 2023 | 3.68 | -0.06 | -1.60% | 3.74 | 3.85 | 3.68 |
| Sep 20, 2023 | 3.81 | -0.02 | -0.52% | 3.83 | 3.87 | 3.73 |
| Sep 19, 2023 | 3.88 | 0.05 | 1.31% | 3.83 | 3.91 | 3.83 |
| Sep 18, 2023 | 3.84 | -0.12 | -3.03% | 3.96 | 3.98 | 3.83 |
| Sep 15, 2023 | 3.99 | -0.13 | -3.16% | 4.12 | 4.14 | 3.93 |
| Sep 14, 2023 | 4.13 | -0.09 | -2.13% | 4.22 | 4.23 | 4.08 |
| Sep 13, 2023 | 4.24 | 0.04 | 0.95% | 4.20 | 4.35 | 4.19 |
| Sep 12, 2023 | 4.22 | -0.16 | -3.65% | 4.38 | 4.38 | 4.19 |
| Sep 11, 2023 | 4.31 | -0.09 | -2.05% | 4.40 | 4.40 | 4.31 |
| Sep 8, 2023 | 4.40 | 0.01 | 0.23% | 4.39 | 4.48 | 4.39 |
| Sep 7, 2023 | 4.32 | 0.04 | 0.93% | 4.28 | 4.32 | 4.28 |
| Sep 6, 2023 | 4.30 | -0.09 | -2.05% | 4.39 | 4.39 | 4.23 |
| Sep 5, 2023 | 4.44 | -0.15 | -3.27% | 4.59 | 4.60 | 4.38 |
| Sep 1, 2023 | 4.54 | 0.09 | 2.02% | 4.45 | 4.64 | 4.38 |
| Aug 31, 2023 | 4.45 | -0.22 | -4.71% | 4.67 | 4.68 | 4.43 |
| Aug 30, 2023 | 4.69 | -0.02 | -0.42% | 4.71 | 4.71 | 4.53 |
| Aug 29, 2023 | 4.63 | 0.00 | 0.00% | 4.63 | 4.67 | 4.59 |
| Aug 28, 2023 | 4.63 | -0.06 | -1.28% | 4.69 | 4.69 | 4.61 |
| Aug 25, 2023 | 4.72 | 0.09 | 1.94% | 4.63 | 4.72 | 4.59 |
Lantern Pharma Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Lantern Pharma Inc. Earnings Release Q3 2023 Lantern Pharma Inc. Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 14.4327 | 12.4825 | 5.90819 | 2.42819 | 1.72642 |
| Selling/General/Admin. Expenses, Total | 5.8298 | 5.02093 | 3.66497 | 1.475 | 1.15432 |
| Research & Development | 8.60295 | 7.57058 | 2.24323 | 0.95319 | 0.5721 |
| Operating Income | -14.4327 | -12.4825 | -5.90819 | -2.42819 | -1.72642 |
| Net Income Before Taxes | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Net Income After Taxes | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Net Income Before Extra. Items | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Net Income | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Income Available to Common Excl. Extra. Items | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Income Available to Common Incl. Extra. Items | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Diluted Net Income | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Diluted Weighted Average Shares | 10.8506 | 10.9049 | 6.22093 | 6.03059 | 6.03059 |
| Diluted EPS Excluding Extraordinary Items | -1.31421 | -1.13371 | -0.94973 | -0.40264 | -0.28628 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -1.31421 | -1.14371 | -0.94973 | -0.40264 | -0.28628 |
| Unusual Expense (Income) | -0.109 | ||||
| Interest Income (Expense), Net Non-Operating | 0.20436 | 0.11948 | |||
| Other, Net | -0.03155 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 4.28627 | 3.82628 | 2.14526 | 4.39482 | 4.0664 |
| Selling/General/Admin. Expenses, Total | 1.73332 | 1.57468 | 1.44296 | 1.406 | 1.40616 |
| Research & Development | 2.55295 | 2.2516 | 0.7023 | 2.98882 | 2.66024 |
| Operating Income | -4.28627 | -3.82628 | -2.14526 | -4.39482 | -4.0664 |
| Net Income Before Taxes | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Net Income After Taxes | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Net Income Before Extra. Items | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Net Income | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Income Available to Common Excl. Extra. Items | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Income Available to Common Incl. Extra. Items | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Diluted Net Income | -3.86777 | -3.38111 | -2.26468 | -4.49239 | -4.12177 |
| Diluted Weighted Average Shares | 10.857 | 10.8571 | 10.8389 | 10.8309 | 10.8758 |
| Diluted EPS Excluding Extraordinary Items | -0.35624 | -0.31142 | -0.20894 | -0.41477 | -0.37899 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.35624 | -0.31142 | -0.20894 | -0.41477 | -0.37899 |
| Unusual Expense (Income) | |||||
| Interest Income (Expense), Net Non-Operating | 0.13378 | 0.07468 | 0.05222 | 0.05503 | 0.02242 |
| Other, Net | 0.28472 | 0.37049 | -0.17165 | -0.15259 | -0.0778 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 58.7227 | 72.7164 | 20.2369 | 1.23282 | 0.44516 |
| Cash and Short Term Investments | 55.1961 | 70.7254 | 19.2292 | 1.23203 | 0.44516 |
| Cash | 37.2018 | 51.5243 | 19.2292 | 1.23203 | 0.44516 |
| Total Assets | 58.8363 | 73.9505 | 20.3596 | 1.43258 | 0.44983 |
| Property/Plant/Equipment, Total - Net | 0.0957 | 0.21619 | 0.02151 | 0.00876 | 0.00467 |
| Other Long Term Assets, Total | 0.01789 | 1.01789 | 0.10121 | 0.191 | 0 |
| Total Current Liabilities | 2.7983 | 2.32617 | 0.55234 | 0.48929 | 0.65163 |
| Payable/Accrued | 2.74541 | 2.17411 | 0.55234 | 0.48929 | 0.11663 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.535 | ||||
| Total Liabilities | 2.7983 | 2.37906 | 0.66084 | 0.48929 | 0.65163 |
| Total Long Term Debt | 0 | 0 | 0.1085 | 0 | 0 |
| Total Equity | 56.038 | 71.5714 | 19.6988 | 0.94328 | -0.2018 |
| Redeemable Preferred Stock | 0.01402 | 0.00743 | |||
| Common Stock | 0.00109 | 0.00111 | 0.00062 | 0.01137 | 0.01137 |
| Additional Paid-In Capital | 95.6912 | 96.6859 | 32.3581 | 7.6696 | 4.10292 |
| Retained Earnings (Accumulated Deficit) | -39.2829 | -25.0229 | -12.6599 | -6.75171 | -4.32352 |
| Total Liabilities & Shareholders’ Equity | 58.8363 | 73.9505 | 20.3596 | 1.43258 | 0.44983 |
| Total Common Shares Outstanding | 10.857 | 11.0888 | 6.22093 | 6.03059 | 6.03059 |
| Prepaid Expenses | 2.98547 | 1.99095 | 1.00769 | 0.00079 | |
| Long Term Debt | 0 | 0.1085 | |||
| Short Term Investments | 17.9943 | 19.2012 | |||
| Accrued Expenses | 0.05289 | 0.15206 | |||
| Other Liabilities, Total | 0 | 0.05289 | |||
| Other Equity, Total | -0.37139 | -0.09269 | |||
| Other Current Assets, Total | 0.54118 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 55.1676 | 58.7227 | 62.0198 | 65.663 | 67.6632 |
| Cash and Short Term Investments | 51.5401 | 55.1961 | 57.8266 | 62.1495 | 65.2165 |
| Cash | 32.4788 | 37.2018 | 39.2579 | 43.3629 | 46.6517 |
| Prepaid Expenses | 3.08633 | 2.98547 | 3.65197 | 3.51349 | 2.44668 |
| Total Assets | 55.5093 | 58.8363 | 62.1644 | 66.3798 | 68.4025 |
| Property/Plant/Equipment, Total - Net | 0.30879 | 0.0957 | 0.12673 | 0.15775 | 0.18029 |
| Other Long Term Assets, Total | 0.03297 | 0.01789 | 0.01789 | 0.55907 | 0.55907 |
| Total Current Liabilities | 2.79319 | 2.7983 | 3.139 | 5.30429 | 3.07385 |
| Payable/Accrued | 2.6736 | 2.74541 | 3.04697 | 5.17359 | 2.91865 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.93382 | 2.7983 | 3.139 | 5.30429 | 3.08715 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Total Equity | 52.5755 | 56.038 | 59.0254 | 61.0755 | 65.3154 |
| Common Stock | 0.00109 | 0.00109 | 0.00109 | 0.00108 | 0.00108 |
| Additional Paid-In Capital | 96.0247 | 95.6912 | 95.3611 | 95.06 | 94.7705 |
| Retained Earnings (Accumulated Deficit) | -43.1506 | -39.2829 | -35.9018 | -33.6371 | -29.1447 |
| Total Liabilities & Shareholders’ Equity | 55.5093 | 58.8363 | 62.1644 | 66.3798 | 68.4025 |
| Total Common Shares Outstanding | 10.857 | 10.857 | 10.857 | 10.8309 | 10.8309 |
| Short Term Investments | 19.0613 | 17.9943 | 18.5687 | 18.7866 | 18.5648 |
| Accrued Expenses | 0.11958 | 0.05289 | 0.09202 | 0.13071 | 0.15519 |
| Other Current Liabilities, Total | |||||
| Other Liabilities, Total | 0.14063 | 0 | 0 | 0 | 0.0133 |
| Other Equity, Total | -0.29968 | -0.37139 | -0.43504 | -0.34848 | -0.31147 |
| Other Current Assets, Total | 0.54118 | 0.54118 | 0.54118 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.2599 | -12.363 | -5.90819 | -2.42819 | -1.72642 |
| Cash From Operating Activities | -12.7675 | -10.5915 | -5.65162 | -2.12792 | -1.27152 |
| Non-Cash Items | 2.09424 | 1.16477 | 1.19224 | 0.11776 | 0.18306 |
| Changes in Working Capital | -0.61186 | 0.59996 | -0.93906 | 0.18088 | 0.27184 |
| Cash From Investing Activities | 0.17927 | -19.5306 | -0.01614 | -0.00572 | 0.00534 |
| Other Investing Cash Flow Items, Total | 0.20711 | -19.5151 | 0.00534 | ||
| Cash From Financing Activities | -2.1825 | 63.4161 | 23.665 | 2.92051 | 0.535 |
| Financing Cash Flow Items | 0 | -4.78382 | -2.74554 | 0 | 0.535 |
| Issuance (Retirement) of Stock, Net | -2.1825 | 68.1999 | 26.302 | 2.92051 | 0 |
| Net Change in Cash | -14.7813 | 33.2951 | 17.9972 | 0.78687 | -0.73118 |
| Cash From Operating Activities | 0.01008 | 0.00676 | 0.00339 | 0.00163 | |
| Capital Expenditures | -0.02784 | -0.0155 | -0.01614 | -0.00572 | |
| Issuance (Retirement) of Debt, Net | 0 | 0.1085 | |||
| Foreign Exchange Effects | -0.01061 | 0.00107 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.86777 | -14.2599 | -10.8788 | -8.61416 | -4.12177 |
| Cash From Operating Activities | -3.75716 | -12.7675 | -10.0986 | -6.06036 | -3.32773 |
| Cash From Operating Activities | 0.00342 | 0.01008 | 0.00732 | 0.00437 | 0.00199 |
| Non-Cash Items | 0.34754 | 2.09424 | 1.76509 | 1.16612 | 0.5284 |
| Changes in Working Capital | -0.24035 | -0.61186 | -0.9922 | 1.3833 | 0.26366 |
| Cash From Financing Activities | 0 | -2.1825 | -2.1825 | -2.1825 | -2.1825 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 | |
| Issuance (Retirement) of Stock, Net | 0 | -2.1825 | -2.1825 | -2.1825 | -2.1825 |
| Issuance (Retirement) of Debt, Net | |||||
| Net Change in Cash | -4.72302 | -14.7813 | -12.7252 | -8.62025 | -5.33143 |
| Cash From Investing Activities | -0.96088 | 0.17927 | -0.42359 | -0.34923 | 0.17652 |
| Capital Expenditures | -0.00888 | -0.02784 | -0.02089 | -0.01418 | |
| Other Investing Cash Flow Items, Total | -0.952 | 0.20711 | -0.4027 | -0.33505 | 0.17652 |
| Foreign Exchange Effects | -0.00498 | -0.01061 | -0.02051 | -0.02816 | 0.00228 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Bios Equity Partners, LP. | Venture Capital | 14.1044 | 1533018 | -323907 | 2023-04-15 | LOW |
| Biological Mimetics, Inc | Corporation | 8.6894 | 944458 | -13807 | 2023-04-15 | LOW |
| Prophase Labs Inc | Corporation | 8.3724 | 910000 | 0 | 2023-04-15 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.3807 | 367454 | 0 | 2023-06-30 | LOW |
| GWM Advisors LLC | Investment Advisor | 1.5776 | 171465 | -650 | 2023-06-30 | LOW |
| Carlson Capital, L.P. | Hedge Fund | 0.874 | 95000 | -29900 | 2023-06-30 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8283 | 90026 | 32252 | 2023-06-30 | LOW |
| CM Management, LLC | Investment Advisor | 0.69 | 75000 | 15000 | 2023-06-30 | LOW |
| Redmond Asset Management, LLC | Investment Advisor | 0.4288 | 46604 | -2585 | 2023-06-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.4131 | 44900 | 20300 | 2023-06-30 | HIGH |
| Keyser (Donald Jeffrey PH.D) | Individual Investor | 0.3857 | 41927 | 0 | 2023-04-15 | LOW |
| Horizon Kinetics LLC | Investment Advisor/Hedge Fund | 0.276 | 30000 | 0 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2553 | 27752 | 0 | 2023-06-30 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.2484 | 27000 | 0 | 2023-06-30 | LOW |
| Newton Investment Management North America, LLC | Investment Advisor | 0.2436 | 26480 | 0 | 2023-06-30 | MED |
| WWM Financial | Investment Advisor | 0.2313 | 25145 | -1333 | 2023-06-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.2276 | 24737 | 13761 | 2023-06-30 | LOW |
| Incrementum AG | Investment Advisor | 0.1738 | 18888 | 0 | 2023-06-30 | MED |
| Sigma Planning Corporation | Investment Advisor | 0.1668 | 18125 | 850 | 2023-06-30 | LOW |
| Commonwealth Financial Network | Investment Advisor | 0.1547 | 16813 | -3373 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lantern Pharma Inc. Company profile
About Lantern Pharma Inc.
Lantern Pharma Inc. is a clinical stage biopharmaceutical company. The Company is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Lantern Pharma Inc. revenues was not reported. Net loss increased from $5.9M to $12.4M. Higher net loss reflects Research and development increase from $2.2M to $7.6M (expense), General and administrative - Balancing v increase of 99% to $4.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$1.13.
| Industry: | Biotechnology & Medical Research (NEC) |
1920 Mckinney Avenue
7th Floor
DALLAS
TEXAS 75201
US
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com